30.32
-0.42 (-1.37%)
| Previous Close | 30.74 |
| Volume | 392,999 |
| Price / Earnings (Forward) | 18.48 |
| Price / Sales | 5.73 |
| Price / Book | 4.86 |
| 52 Weeks Range | |
| TTM Dividend Yield | 1.10% |
| Profit Margin | 26.15% |
| Operating Margin (TTM) | 33.00% |
| Diluted EPS (TTM) | 1.35 |
| Quarterly Revenue Growth (YOY) | 7.90% |
| Quarterly Earnings Growth (YOY) | 21.50% |
| Total Debt/Equity (MRQ) | 15.14% |
| Current Ratio (MRQ) | 3.41 |
| Operating Cash Flow (TTM) | 1.65 B |
| Levered Free Cash Flow (TTM) | 1.20 B |
| Return on Assets (TTM) | 14.01% |
| Return on Equity (TTM) | 25.81% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (AU) | Mixed | Mixed |
| Medical Instruments & Supplies (Global) | Bullish | Mixed | |
| Stock | RESMED CDI 10:1 [RMD] | - | - |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -2.5 |
| Average | -0.88 |
|
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea, combined with aging populations and increasing prevalence of obesity, is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Mid Core |
| % Held by Institutions | 9.16% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |